Literature DB >> 27791031

FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.

Xiaoyong Fu1, Rinath Jeselsohn2, Resel Pereira1, Emporia F Hollingsworth3, Chad J Creighton4, Fugen Li2, Martin Shea5, Agostina Nardone5, Carmine De Angelis5, Laura M Heiser6, Pavana Anur7, Nicholas Wang6, Catherine S Grasso6, Paul T Spellman7, Obi L Griffith8, Anna Tsimelzon5, Carolina Gutierrez3, Shixia Huang9, Dean P Edwards10, Meghana V Trivedi11, Mothaffar F Rimawi5, Dolores Lopez-Terrada3, Susan G Hilsenbeck5, Joe W Gray6, Myles Brown2, C Kent Osborne12, Rachel Schiff13.   

Abstract

Forkhead box protein A1 (FOXA1) is a pioneer factor of estrogen receptor α (ER)-chromatin binding and function, yet its aberration in endocrine-resistant (Endo-R) breast cancer is unknown. Here, we report preclinical evidence for a role of FOXA1 in Endo-R breast cancer as well as evidence for its clinical significance. FOXA1 is gene-amplified and/or overexpressed in Endo-R derivatives of several breast cancer cell line models. Induced FOXA1 triggers oncogenic gene signatures and proteomic profiles highly associated with endocrine resistance. Integrated omics data reveal IL8 as one of the most perturbed genes regulated by FOXA1 and ER transcriptional reprogramming in Endo-R cells. IL-8 knockdown inhibits tamoxifen-resistant cell growth and invasion and partially attenuates the effect of overexpressed FOXA1. Our study highlights a role of FOXA1 via IL-8 signaling as a potential therapeutic target in FOXA1-overexpressing ER-positive tumors.

Entities:  

Keywords:  FOXA1; breast cancer; endocrine resistance; estrogen receptor; transcriptional reprogramming

Mesh：

Substances：

Year:  2016        PMID： 27791031      PMCID： PMC5087040          DOI： 10.1073/pnas.1612835113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  73 in total

1.  Genome-wide analysis of estrogen receptor binding sites.

Authors:  Jason S Carroll; Clifford A Meyer; Jun Song; Wei Li; Timothy R Geistlinger; Jérôme Eeckhoute; Alexander S Brodsky; Erika Krasnickas Keeton; Kirsten C Fertuck; Giles F Hall; Qianben Wang; Stefan Bekiranov; Victor Sementchenko; Edward A Fox; Pamela A Silver; Thomas R Gingeras; X Shirley Liu; Myles Brown
Journal:  Nat Genet       Date:  2006-10-01       Impact factor: 38.330

2.  CEAS: cis-regulatory element annotation system.

Authors:  Hyunjin Shin; Tao Liu; Arjun K Manrai; X Shirley Liu
Journal:  Bioinformatics       Date:  2009-08-18       Impact factor: 6.937

Review 3.  Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer.

Authors:  Xiaoyong Fu; C Kent Osborne; Rachel Schiff
Journal:  Breast       Date:  2013-09-05       Impact factor: 4.380

4.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Authors:  J M Harvey; G M Clark; C K Osborne; D C Allred
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

5.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

6.  Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Authors:  Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

7.  Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance.

Authors:  Mathieu Lupien; Clifford A Meyer; Shannon T Bailey; Jérôme Eeckhoute; Jennifer Cook; Thomas Westerling; Xiaoyang Zhang; Jason S Carroll; Daniel R Rhodes; X Shirley Liu; Myles Brown
Journal:  Genes Dev       Date:  2010-10-01       Impact factor: 11.361

8.  FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer.

Authors:  C Gong; K Fujino; L J Monteiro; A R Gomes; R Drost; H Davidson-Smith; S Takeda; U S Khoo; J Jonkers; D Sproul; E W-F Lam
Journal:  Oncogene       Date:  2014-12-22       Impact factor: 9.867

9.  Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer.

Authors:  Nathalie Quenel-Tueux; Marc Debled; Justine Rudewicz; Gaetan MacGrogan; Marina Pulido; Louis Mauriac; Florence Dalenc; Thomas Bachelot; Barbara Lortal; Christelle Breton-Callu; Nicolas Madranges; Christine Tunon de Lara; Marion Fournier; Hervé Bonnefoi; Hayssam Soueidan; Macha Nikolski; Audrey Gros; Catherine Daly; Henry Wood; Pamela Rabbitts; Richard Iggo
Journal:  Br J Cancer       Date:  2015-07-14       Impact factor: 7.640

Review 10.  Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells.

Authors:  Jagdeep K Singh; Bruno M Simões; Sacha J Howell; Gillian Farnie; Robert B Clarke
Journal:  Breast Cancer Res       Date:  2013       Impact factor: 6.466
View more
  61 in total

1.  FOXA1 Protein Expression in ER+ and ER- Breast Cancer in Relation to Parity and Breastfeeding in Black and White Women.

Authors:  Ting-Yuan David Cheng; Song Yao; Angela R Omilian; Thaer Khoury; Matthew F Buas; Rochelle Payne-Ondracek; Sirinapa Sribenja; Wiam Bshara; Chi-Chen Hong; Elisa V Bandera; Warren Davis; Michael J Higgins; Christine B Ambrosone
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-12-23       Impact factor: 4.254

2.  Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer.

Authors:  Ahmed Basudan; Nolan Priedigkeit; Ryan J Hartmaier; Ethan S Sokol; Amir Bahreini; Rebecca J Watters; Michelle M Boisen; Rohit Bhargava; Kurt R Weiss; Maria M Karsten; Carsten Denkert; Jens-Uwe Blohmer; Jose P Leone; Ronald L Hamilton; Adam M Brufsky; Esther Elishaev; Peter C Lucas; Adrian V Lee; Steffi Oesterreich
Journal:  Mol Cancer Res       Date:  2018-10-24       Impact factor: 5.852

3.  Embryonic transcription factor SOX9 drives breast cancer endocrine resistance.

Authors:  Rinath Jeselsohn; MacIntosh Cornwell; Matthew Pun; Gilles Buchwalter; Mai Nguyen; Clyde Bango; Ying Huang; Yanan Kuang; Cloud Paweletz; Xiaoyong Fu; Agostina Nardone; Carmine De Angelis; Simone Detre; Andrew Dodson; Hisham Mohammed; Jason S Carroll; Michaela Bowden; Prakash Rao; Henry W Long; Fugen Li; Mitchell Dowsett; Rachel Schiff; Myles Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-15       Impact factor: 11.205

4.  Aspirin inhibits platelets from reprogramming breast tumor cells and promoting metastasis.

Authors:  Kelly E Johnson; Julia R Ceglowski; Harvey G Roweth; Jodi A Forward; Mason D Tippy; Saleh El-Husayni; Rajesh Kulenthirarajan; Michael W Malloy; Kellie R Machlus; Wendy Y Chen; Joseph E Italiano; Elisabeth M Battinelli
Journal:  Blood Adv       Date:  2019-01-22

5.  Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance.

Authors:  Mingjun Bi; Zhao Zhang; Yi-Zhou Jiang; Pengya Xue; Hu Wang; Zhao Lai; Xiaoyong Fu; Carmine De Angelis; Yue Gong; Zhen Gao; Jianhua Ruan; Victor X Jin; Elisabetta Marangoni; Elodie Montaudon; Christopher K Glass; Wei Li; Tim Hui-Ming Huang; Zhi-Ming Shao; Rachel Schiff; Lizhen Chen; Zhijie Liu
Journal:  Nat Cell Biol       Date:  2020-05-18       Impact factor: 28.824

Review 6.  Comprehensive Review of Molecular Mechanisms and Clinical Features of Invasive Lobular Cancer.

Authors:  Nikhil Pramod; Akanksha Nigam; Mustafa Basree; Resham Mawalkar; Saba Mehra; Neelam Shinde; Gary Tozbikian; Nicole Williams; Sarmila Majumder; Bhuvaneswari Ramaswamy
Journal:  Oncologist       Date:  2021-03-16

7.  Genetic Mechanisms of Immune Evasion in Colorectal Cancer.

Authors:  Catherine S Grasso; Marios Giannakis; Daniel K Wells; Tsuyoshi Hamada; Xinmeng Jasmine Mu; Michael Quist; Jonathan A Nowak; Reiko Nishihara; Zhi Rong Qian; Kentaro Inamura; Teppei Morikawa; Katsuhiko Nosho; Gabriel Abril-Rodriguez; Charles Connolly; Helena Escuin-Ordinas; Milan S Geybels; William M Grady; Li Hsu; Siwen Hu-Lieskovan; Jeroen R Huyghe; Yeon Joo Kim; Paige Krystofinski; Mark D M Leiserson; Dennis J Montoya; Brian B Nadel; Matteo Pellegrini; Colin C Pritchard; Cristina Puig-Saus; Elleanor H Quist; Ben J Raphael; Stephen J Salipante; Daniel Sanghoon Shin; Eve Shinbrot; Brian Shirts; Sachet Shukla; Janet L Stanford; Wei Sun; Jennifer Tsoi; Alexander Upfill-Brown; David A Wheeler; Catherine J Wu; Ming Yu; Syed H Zaidi; Jesse M Zaretsky; Stacey B Gabriel; Eric S Lander; Levi A Garraway; Thomas J Hudson; Charles S Fuchs; Antoni Ribas; Shuji Ogino; Ulrike Peters
Journal:  Cancer Discov       Date:  2018-03-06       Impact factor: 39.397

8.  AhR ligand aminoflavone suppresses α6-integrin-Src-Akt signaling to attenuate tamoxifen resistance in breast cancer cells.

Authors:  Petreena S Campbell; Nicole Mavingire; Salma Khan; Leah K Rowland; Jonathan V Wooten; Anna Opoku-Agyeman; Ashley Guevara; Ubaldo Soto; Fiorella Cavalli; Andrea Irene Loaiza-Pérez; Gayathri Nagaraj; Laura J Denham; Olayemi Adeoye; Brittany D Jenkins; Melissa B Davis; Rachel Schiff; Eileen J Brantley
Journal:  J Cell Physiol       Date:  2018-08-04       Impact factor: 6.384

9.  The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells.

Authors:  Yuan Yin; Chuan-Ming Xie; Hua Li; Mingjia Tan; Guoan Chen; Rachel Schiff; Xiufang Xiong; Yi Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-23       Impact factor: 11.205

10.  The 3D genomic landscape of differential response to EGFR/HER2 inhibition in endocrine-resistant breast cancer cells.

Authors:  Yini Yang; Lavanya Choppavarapu; Kun Fang; Alireza S Naeini; Bakhtiyor Nosirov; Jingwei Li; Ke Yang; Zhijing He; Yufan Zhou; Rachel Schiff; Rong Li; Yanfen Hu; Junbai Wang; Victor X Jin
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2020-09-19       Impact factor: 4.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.